Investigational drug · Phase 3
Dalpiciclib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
92
Any phase or sponsor naming "Dalpiciclib"
First trial start
2025
Nov 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Dalpiciclib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Dalpiciclib" as an intervention, largest first.
- CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer(Cinnamon)Pivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT07432178 · 2,288 participants (planned) · Start Apr 3, 2026 · Primary completion Mar 31, 2031
Drug: Dalpiciclib+AI ± OFS; TC (Docetaxel + Cyclophosphamide) × 4 cycles- endocrine therapy · For: Breast Cancer
Sites: Shanghai, China
- Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyPivotal-lookingRecruiting
Fujian Cancer HospitalGovernment (non-federal)
NCT07581834 · 2,000 participants (planned) · Start Jan 21, 2026 · Primary completion Dec 31, 2031
Drug: Dalpiciclib 125mg; Dalpiciclib 100mg and 1 more · For: Breast Diseases; Breast Neoplasms; Dalpiciclib and 3 more
Sites: Fuzhou, China; Chengdu, China
- Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07005557 · 1,244 participants (planned) · Start Jun 15, 2025 · Primary completion May 15, 2030
Drug: Chemotherapy; CDK4/6 Inhibitor and 1 more · For: Breast Cancer; Adjuvant Therapy
The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
NCT06341894 · 1,163 participants (planned) · Start Nov 17, 2023 · Primary completion Jun 2027
Drug: Dalpiciclib; Endocrine therapy · For: Early Breast Cancer
Sites: Nanjing, China
- A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.Pivotal-lookingRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07354022 · 912 participants (planned) · Start May 5, 2026 · Primary completion Dec 2028
Drug: HRS-8080 Tablet ; Dalpiciclib Isethionate; Fulvestrant injection ;Dalpiciclib Isethionate · For: Locally Advanced or Metastatic Breast Cancer
Sites: Beijing, China
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)Pivotal-lookingNot yet recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06099990 · 660 participants (planned) · Start Oct 2023 · Primary completion Dec 2028
Drug: dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets; placebo; abiraterone acetate tablets; prednisone tablets · For: High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
- SNF Platform Study of HR+/ HER2-advanced Breast CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05594095 · 620 participants (planned) · Start Dec 30, 2022 · Primary completion Dec 1, 2025
Drug: PIK3CA inhibitor; AKT inhibitor and 17 more · For: Breast Neoplasm; Breast Cancer; Hormone Receptor Positive Tumor and 2 more
Sites: Shanghai, China
- Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT07615751 · 502 participants (planned) · Start Feb 12, 2025 · Primary completion Dec 30, 2028
Drug: Pyrotinib 320mg po qd d1-d21 q3w and Trastuzumab 600mg IH d1 q3w Combined with Dalpicicli 125mg po gd d1-d21 q4w; Pyrotinib 320mg po qd d1-d21 q3w and Trastuzumab 600mg IH d1 q3w Combined with Docetaxel 75mg/m² ivgtt d1 q3w, · For: Breast Cancer
Sites: Shanghai, China
- Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07826052 · 494 participants (planned) · Start Sep 15, 2026 · Primary completion Sep 30, 2031
Drug: CDK4/6 inhibitor; Endocrine Therapy (Optional) · For: Breast Cancer; Adjuvant Therapy
Newest research
PubMed records naming it or its code names, newest first.
- A miR-221-3p-CDKN1B-CDK4/β-catenin axis couples tumor progression with response to CDK4/6 inhibition in intrahepatic cholangiocarcinoma.
Tang YH, Wang JC, Chen JB, et al. · Pharmacol Res 2026
- Discovery of rigid linker-based CDK4/6 PROTACs for the treatment of breast cancer.
Pan G, Li Y, Tan J, et al. · Bioorg Chem 2026
- Hepatic adverse events with CDK4/6 inhibitors: a systematic review combining meta-analysis and FAERS database.
Tang Y, Li Y, Zhang C, et al. · Expert Opin Drug Saf 2026
- Efficacy and safety of dalpiciclib combined with endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer: a real-world study.
Li Y, Li B, Ma X, et al. · Front Oncol 2026
- Dalpiciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer and visceral crisis: a multicenter, nonrandomized, phase 2 DARVIN trial.
Mo H, Teng Y, Cai L, et al. · Nat Cancer 2026
- Dalpiciclib combined with endocrine therapy for patients with HR+/HER2- metastatic breast cancer: a multicenter real-world study.
Chen X, Lin L, He G, et al. · Ther Adv Med Oncol 2026
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.